Immune Therapeutic Strategies in Chronic Hepatitis B Virus Infection: Virus or Inflammation Control?

Bertoletti, Antonio; Gehring, Adam J.
December 2013
PLoS Pathogens;Dec2013, Vol. 9 Issue 12, p1
Academic Journal
The article discusses immune therapeutic strategies in chronic hepatitis B virus (HBV) infection. It describes the immunological profile of HBV control, as well as the strategies for the restoration of adaptive immunity in chronic HBV patients. The article also discusses ways to directly stimulate intrahepatic innate immunity and explores whether the reduction of liver inflammation is a valuable therapeutic strategy for chronic HBV infection (CHB) infection.


Related Articles

  • Therapeutic options for chronic hepatitis B in 2013. Asselah, Tarik; Marcellin, Patrick // Hot Topics in Viral Hepatitis;2013, Vol. 9 Issue 28, p8 

    In recent years, many improvements have been made in prevention and treatment of hepatitis B virus (HBV) infection--one of the major causes of chronic hepatic diseases: cirrhosis and hepatocellular carcinoma (HCC). The aim of this therapy is preventing the progression of the disease through...

  • Trends in the Diagnosis and Treatment of Chronic Hepatitis B in Karachi, Pakistan. ANJUM, FAKHSHEENA; GHAYAS, SANA; SHAFI, VIQAS; BASHIR, LUBNA; NAZ, SHAZIA // Journal of Medicine;2013, Vol. 14 Issue 1, p57 

    Aims: Aim of this study was to analyze diagnostic and therapeutic trends of physicians regarding Chronic Hepatitis B (CHB) in Karachi since Pakistan is endemic area for viral hepatitis B. Methods: A questionnaire was distributed to about 100 physicians / doctors in different hospitals of...

  • Long-Term Treatment Efficacy and Safety of Clevudine Therapy in Naïve Patients with Chronic Hepatitis B. Bum Su Choung; In Hee Kim; Byung Jun Jeon; Seok Lee; Seong Hun Kim; Sang Wook Kim; Seung Ok Lee; Soo Teik Lee; Dae-Ghon Kim // Gut & Liver;Oct2012, Vol. 6 Issue 4, p486 

    Background/Aims: Clevudine (CLV) has potent antiviral activity against chronic hepatitis B (CHB) virus infection. The long-term efficacy and safety of CLV therapy in naïve patients with CHB were investigated. Methods: In this retrospective study, 152 naïve Korean patients with CHB who...

  • Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study. Hosaka, Tetsuya; Suzuki, Fumitaka; Kobayashi, Masahiro; Seko, Yuya; Kawamura, Yusuke; Sezaki, Hitomi; Akuta, Norio; Suzuki, Yoshiyuki; Saitoh, Satoshi; Arase, Yasuji; Ikeda, Kenji; Kobayashi, Mariko; Kumada, Hiromitsu // Journal of Gastroenterology;Aug2013, Vol. 48 Issue 8, p930 

    Background: Clearance of hepatitis B surface antigen (HBsAg) is considered the ultimate goal in chronic hepatitis B treatment. One treatment option is long-term nucleot(s)ide analog (NA) therapy. We followed a group of long-term NA therapy patients to evaluate the efficacy of this treatment in...

  • Coexistence of HBsAg and HBsAb in a difficult-totreat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination. Galati, Giovanni; De Vincentis, Antonio; Vespasiani-Gentilucci, Umberto; Gallo, Paolo; Vincenti, Donatella; Solmone, Maria Carmela; Dell'Unto, Chiara; Picardi, Antonio // BMC Gastroenterology;2014, Vol. 14 Issue 1, p1 

    Background Some reports have documented the coexistence of Hepatitis B surfage Antigen (HBsAg) and anti-HBsAg antibodies (HBsAb) in patients with chronic hepatitis B (CHB), often in the absence of amino acid substitutions in the HBsAg sequences of the Hepatitis B Virus (HBV) genome able to...

  • An Efficient Synthesis of Enantiopure (R)-heteroarylpyrimidine Analogs. Xiu-Yan Yang; Guang-Qiang Xia; Xiao-Kui Wang; Zhi-Bing Zheng; Dong-Mei Zhao; Guo-Ming Zhao; Song Li // Molecules;Sep2013, Vol. 18 Issue 9, p11144 

    An efficient synthesis of enantiopure (R)-heteroarylpyrimidine analogs is described here, which involves introduction of a chiral group, formation and separation of diasteroisomers and final transformation of an amide to an ester. The absolute configuration of the enantiopure HAPs is confirmed...

  • Regulation of T cell proliferation by JMJD6 and PDGF-BB during chronic hepatitis B infection. Cai-Feng Chen; Xia Feng; Hui-Yu Liao; Wen-Jing Jin; Jian Zhang; Yu Wang; Lu-Lu Gong; Jing-Jun Liu; Xiao-Hui Yuan; Bin-Bin Zhao; Ding Zhang; Guo-Feng Chen; Ying Wan; Jian Guo; Hui-Ping Yan; You-Wen He // Scientific Reports;9/19/2014, p1 

    T cell functional exhaustion during chronic hepatitis B virus (HBV) infection may contribute to the failed viral clearance; however, the underlying molecular mechanisms remain largely unknown. Here we demonstrate that jumonji domain-containing protein 6 (JMJD6) is a potential regulator of T cell...

  • Antiviral efficacy of adefovir dipivoxil in the treatment of chronic hepatitis B subjects from Indian subcontinent. Ismail, A. M.; Ramachandran, J.; Kannangai, R.; Abraham, P. // Indian Journal of Medical Microbiology;Jan2014, Vol. 32 Issue 1, p60 

    Adefovir is one of the therapeutic options for the treatment of chronic hepatitis B. A total of 30 adefovir-experienced subjects with the median treatment duration of 12 (interquartile range (IQR) 6-18) months were studied. Virological response was measured by hepatitis B virus deoxyribonucleic...

  • TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Martin, Perrine; Dubois, Clarisse; Jacquier, Emilie; Dion, Sarah; Mancini-Bourgine, Maryline; Godon, Ophélie; Kratzer, Roland; Lelu-Santolaria, Karine; Evlachev, Alexei; Meritet, Jean-François; Schlesinger, Yasmin; Villeval, Dominique; Strub, Jean-Marc; Van Dorsselaer, Alain; Marchand, Jean-Baptiste; Geist, Miche; Brandely, Renée; Findeli, Annie; Boukhebza, Houda; Menguy, Thierry // Gut;Dec2015, Vol. 64 Issue 12, p1961 

    Objective To assess a new adenovirus-based immunotherapy as a novel treatment approach to chronic hepatitis B (CHB). Methods TG1050 is a non-replicative adenovirus serotype 5 encoding a unique large fusion protein composed of a truncated HBV Core, a modified HBV Polymerase and two HBV Envelope...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics